The Russian Direct Investment Fund (RDIF) and the N.F. Gamaleya Research Center announced AstraZeneca has accepted the RDIF proposal and will begin clinical trials of its vaccine in combination with the Sputnik V adenoviral vector of the 26th serotype, by the end of 2020.
Read More
